Petri Polonen
Overview
Explore the profile of Petri Polonen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Umeda M, Hiltenbrand R, Michmerhuizen N, Barajas J, Thomas M, Arthur B, et al.
medRxiv
. 2025 Feb;
PMID: 39974131
Leukemias with rearrangements exhibit heterogeneous phenotypes correlated to fusion partners, whereas the mechanism responsible for this heterogeneity is poorly understood. Through genome-wide mutational and transcriptional analyses of 177 -rearranged leukemias,...
2.
Wang Q, Boccalatte F, Xu J, Gambi G, Nadorp B, Akter F, et al.
J Exp Med
. 2025 Feb;
222(4).
PMID: 39969525
While the mutational landscape across early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and ETP-like leukemia is known, establishing a unified framework that activates stem cell genes characteristic of these tumors...
3.
Aijala V, Harkonen J, Mantere T, Elomaa H, Sirnio P, Pohjanen V, et al.
J Pathol
. 2025 Feb;
265(4):408-421.
PMID: 39917902
Micropapillary colorectal adenocarcinoma is a morphologic subtype of colorectal cancer (CRC) with insufficiently characterized prognostic significance and biological features. We analyzed the histopathological, immunological, and prognostic features of micropapillary adenocarcinoma...
4.
Hughes A, Polonen P, Teachey D
Haematologica
. 2025 Jan;
PMID: 39781622
While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly...
5.
Gower M, Li X, Aguilar-Navarro A, Lin B, Fernandez M, Edun G, et al.
Sci Transl Med
. 2025 Jan;
17(779):eadr2012.
PMID: 39742502
T-lineage acute lymphoblastic leukemia (ALL) is an aggressive cancer comprising diverse subtypes that are challenging to stratify using conventional immunophenotyping. To gain insights into subset-specific therapeutic vulnerabilities, we performed an...
6.
Xu J, Chen C, Sussman J, Yoshimura S, Vincent T, Polonen P, et al.
Nat Cancer
. 2024 Nov;
6(1):102-122.
PMID: 39587259
Refractoriness to initial chemotherapy and relapse after remission are the main obstacles to curing T cell acute lymphoblastic leukemia (T-ALL). While tumor heterogeneity has been implicated in treatment failure, the...
7.
Polonen P, Mullighan C, Teachey D
Blood
. 2024 Oct;
PMID: 39357057
Cure rates for patients with acute lymphoblastic leukemia (ALL) have improved markedly in recent decades, in part due to risk stratification incorporating leukemia genomics, response to treatment, and clinical features...
8.
Teachey D, Newman H, Lee S, Polonen P, Shraim R, Li Y, et al.
Res Sq
. 2024 Aug;
PMID: 39184069
The influence of genetic ancestry on biology, survival outcomes, and risk stratification in T-cell Acute Lymphoblastic Leukemia (T-ALL) has not been explored. Genetic ancestry was genomically-derived from DNA-based single nucleotide...
9.
Polonen P, Di Giacomo D, Seffernick A, Elsayed A, Kimura S, Benini F, et al.
Nature
. 2024 Aug;
632(8027):1082-1091.
PMID: 39143224
T-lineage acute lymphoblastic leukaemia (T-ALL) is a high-risk tumour that has eluded comprehensive genomic characterization, which is partly due to the high frequency of noncoding genomic alterations that result in...
10.
Kimura S, Park C, Montefiori L, Iacobucci I, Polonen P, Gao Q, et al.
Cancer Discov
. 2024 Jun;
14(10):1838-1859.
PMID: 38916500
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand...